Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies.
about
Treatment with disease modifying drugs for people with a first clinical attack suggestive of multiple sclerosisThe Therapeutic Potential of the Ketogenic Diet in Treating Progressive Multiple SclerosisFatigue in Multiple Sclerosis: Neural Correlates and the Role of Non-Invasive Brain StimulationTreatment strategies for multiple sclerosis: When to start, when to change, when to stop?A comparison between the pathophysiology of multiple sclerosis and normal pressure hydrocephalus: is pulse wave encephalopathy a component of MS?Alemtuzumab in the treatment of multiple sclerosis: patient selection and special considerationsComparative efficacy of alemtuzumab and established treatment in the management of multiple sclerosisControl of autoimmune CNS inflammation by astrocytesThe Swiss Multiple Sclerosis Cohort-Study (SMSC): A Prospective Swiss Wide Investigation of Key Phases in Disease Evolution and New Treatment OptionsTreatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis.Patient satisfaction with the BETACONNECT™ autoinjector for interferon beta-1bAlemtuzumab Use in Clinical Practice: Recommendations from European Multiple Sclerosis Experts.Assessment of treatment patterns associated with injectable disease-modifying therapy among relapsing-remitting multiple sclerosis patientsTwo decades of subcutaneous glatiramer acetate injection: current role of the standard dose, and new high-dose low-frequency glatiramer acetate in relapsing-remitting multiple sclerosis treatment.Current perspectives on interferon Beta-1b for the treatment of multiple sclerosisMultiple sclerosis: overview of disease-modifying agentsBlocking GluR2-GAPDH ameliorates experimental autoimmune encephalomyelitisSeeking balance: Potentiation and inhibition of multiple sclerosis autoimmune responses by IL-6 and IL-10.Utility of the rio score and modified rio score in korean patients with multiple sclerosis.Medication use in a large international sample of people with multiple sclerosis: associations with quality of life, relapse rate and disabilityCooccurrence of Multiple Sclerosis and Idiopathic Basal Ganglia Calcification.The Use of Immunosuppressant Therapy for Multiple Sclerosis in Italy: A Multicenter Retroprospective Study.Design of TRUST, a non-interventional, multicenter, 3-year prospective study investigating an integrated patient management approach in patients with relapsing-remitting multiple sclerosis treated with natalizumab.dNP2 is a blood-brain barrier-permeable peptide enabling ctCTLA-4 protein delivery to ameliorate experimental autoimmune encephalomyelitisSpasticity in multiple sclerosis and role of glatiramer acetate treatment.Associations of Lifestyle, Medication, and Socio-Demographic Factors with Disability in People with Multiple Sclerosis: An International Cross-Sectional Study.Comparative evaluation of patients' and physicians' satisfaction with interferon beta-1b therapy.Persistency, medication prescribing patterns, and medical resource use associated with multiple sclerosis patients receiving oral disease-modifying therapies: a retrospective medical record review.Multiple functional therapeutic effects of TnP: A small stable synthetic peptide derived from fish venom in a mouse model of multiple sclerosis.Silencing of Abcc8 or inhibition of newly upregulated Sur1-Trpm4 reduce inflammation and disease progression in experimental autoimmune encephalomyelitis.Reasons for discontinuation of subcutaneous interferon β-1a three times a week among patients with multiple sclerosis: a real-world cohort studyA discrete-choice experiment to determine patient preferences for injectable multiple sclerosis treatments in Germany.Disability may influence patient willingness to participate in decision making on first-line therapy in multiple sclerosis.High-Density Peptide Microarray Analysis of IgG Autoantibody Reactivities in Serum and Cerebrospinal Fluid of Multiple Sclerosis Patients.Safety and Tolerability of Delayed-Release Dimethyl Fumarate Administered with Interferon Beta or Glatiramer Acetate in Relapsing-Remitting Multiple Sclerosis.A Diet Mimicking Fasting Promotes Regeneration and Reduces Autoimmunity and Multiple Sclerosis Symptoms.Quantitative analysis of multiple sclerosis patients' preferences for drug treatment: a best-worst scaling studyMental toughness, sleep disturbances, and physical activity in patients with multiple sclerosis compared to healthy adolescents and young adultsIL-10-dependent Tr1 cells attenuate astrocyte activation and ameliorate chronic central nervous system inflammationHealth insurance affects the use of disease-modifying therapy in multiple sclerosis.
P2860
Q24185806-24E0CBCF-57D5-48DF-AF2A-C52FB0CAB5DEQ26769966-ED6394AD-5644-46B1-9F90-5E854A088DFEQ26773166-9110F9F2-581E-43EA-B579-09BA268F9F90Q26798434-7C82C7D1-8E77-42A0-8A92-8A125E00CA34Q27302357-3C8D23E4-6AD0-45CC-8145-79C31A3A9896Q28077000-B9D8C310-A256-41BE-84ED-0763EED5D010Q28081636-71A191A2-DA00-4F30-ABDA-BEEC7A3AF9BBQ28084132-3B2F445D-AC8B-4D9A-931B-6F822933610BQ28601505-16E6E376-5551-4617-ABFE-976DBD91E219Q30234672-F3E65D17-CF92-44B4-864E-4E59D8936971Q30406774-98567127-1BD3-4BCE-B41B-A6F0822AC949Q30490389-5D55FD6E-BB60-4BF7-8B2C-9B5A8A79DB65Q33764067-01FFC601-D953-4B63-88CC-0629D791F2CAQ34090086-489E3DF3-D78A-4868-B0FF-BE837DD52E44Q34253488-2A8AE9E5-3272-442B-9585-355EC31F1DB4Q34342662-6D11EDB7-ABB1-4C37-BACE-5D09523797F3Q35469598-149D59CA-A273-4C68-839C-0DF9F9D7F28EQ35625089-945286B7-F12F-4517-9CF3-DB67BA78F217Q35641688-4A80A9D0-1769-4A54-A73E-B00E7097D8ECQ35866381-2F2E153C-1892-484A-B7D2-3CB65A0DC23AQ36006267-9D164FF3-34CE-4171-82EB-97A0543141CDQ36062456-07485291-34A9-47E3-8C26-8AF5597FFE0AQ36073992-7B9E6037-7A0B-4169-BB80-F197845BADEFQ36085336-710ABE33-58EE-4436-8063-44F2D0361B9AQ36109866-46BC8083-9753-4590-B67F-2ADD8253EB52Q36112918-9DBE1782-8180-4B45-819D-CFAC0760F378Q36139493-2047A68A-7917-42A2-8CB2-122916C55F5AQ36147567-4750D728-AAC5-4D12-9972-E325D9FA4A64Q36290143-FDC2CC21-DBF7-481C-8BB8-9164ABF4572DQ36298402-AC66FFA0-3E7D-4E6D-9BE6-69CEE8C955DDQ36320930-E3358271-1659-42F4-908D-721331AA06D6Q36667801-730B6C3E-E628-413D-BFE0-39AA2AC4ED1EQ36762515-BE1885BD-FE8B-445D-810F-26C08419C75DQ36778303-71074782-FB1C-4EE8-A4C9-A8FB31F04665Q36951371-16A38B30-C79D-46CF-970F-1B57CC1F3195Q36984189-AC38A18B-A4D5-4CF9-AB6F-BBFAF6D03B5EQ37027705-278D7AAB-014D-429D-87A1-94783E5939A1Q37058811-7C95386F-A312-43B6-AD65-3473AA439B39Q37081950-9169CDFF-F5B3-4267-9EE2-AE46AC3D6B21Q37158954-C8834948-6A09-4EB0-843F-5205936D7A4B
P2860
Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies.
description
2014 nî lūn-bûn
@nan
2014 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Multiple sclerosis: current an ...... pies and treatment strategies.
@ast
Multiple sclerosis: current an ...... pies and treatment strategies.
@en
type
label
Multiple sclerosis: current an ...... pies and treatment strategies.
@ast
Multiple sclerosis: current an ...... pies and treatment strategies.
@en
prefLabel
Multiple sclerosis: current an ...... pies and treatment strategies.
@ast
Multiple sclerosis: current an ...... pies and treatment strategies.
@en
P1476
Multiple sclerosis: current an ...... pies and treatment strategies.
@en
P2093
Dean M Wingerchuk
Jonathan L Carter
P304
P356
10.1016/J.MAYOCP.2013.11.002
P407
P577
2014-02-01T00:00:00Z